DUPILUMAB PROVIDES ACCEPTABLE SAFETY AND SUSTAINED EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Lisa A. Beck · Mette Deleuran · Robert Bissonnette · Marjolein de Bruin-Weller · · Ryszard Galus · Takeshi Nakahara · Seong Jun Seo · Faisal A. Khokhar · Jignesh Vakil · · Jing Xiao · Ainara Rodriguez Marco · Noah A. Levit · John T. O'Malley · Arsalan Shabbir

American Journal of Clinical Dermatology

DUPILUMAB OPEN-LABEL STUDY UP TO 4 YEARS

Including patients who switched to biweekly dosing



300mg qw

2677 patients in 14 parent studies were treated with 300 mg dupilumab weekly for up to 204 weeks



300mg q2w

226 of these patients transitioned to 300 mg dupilumab every 2 weeks

SAFETY

The safety profile of dupilumab was acceptable and consistent with previously reported data. Most treatment-emergent adverse events (TEAEs) were of mild-to-moderate severity



These included nasopharyngitis, atopic dermatitis, upper respiratory tract infection, oral herpes, conjunctivitis, injection-site reaction, and headache

EFFICACY

Mean percent improvement in EASI and Pruritus NRS from baseline of parent study to Week 204

EASI 91%

improvement in Eczema Area and Severity Index Itch 69%

improvement in Pruritus Numerical Rating Scale

EFFICACY AFTER DOSING SWITCH



98% of patients who transitioned from qw to q2w dosing had achieved low burden of itch and mild disease (NRS score ≤ 4 or EASI ≤ 7) at the time of the switch



83% of patients maintained this stringent response for a continuous 6 months following the switch in dose regimen

COMPLIANCE

98%

Treatment compliance

4%

Treatment discontinuation due to TEAEs

DUPILUMAB TREATMENT UP TO 4 YEARS

DUPILUMAB

- Well tolerated and acceptable safety profile
- Efficacy maintained throughout and during switch to approved q2w dose
- Supports long-term, continuous use of dupilumab

×





